SFN functions as an effective histone deacetylase (HDAC) inhibitor, contributing to its cancer-preventive mechanisms which are partially linked to the suppression of phase I detoxification enzymes, including cytochrome P450, family 1, subfamily A, polypeptide 1 (CYP1A1) and CYP2B1/2, and induction of phase II enzymes such as NAD(P)H quinone oxidoreductase 1 (NQO1) and glutathione S-transferase (GST) [62,63]. The gene discussed is NQO1; the disease is cancer.